This relevant grant from FINEP, in the amount of R$ 13,693,706.67, with a contribution from Nintx in the amount of R$ 1,066,320.00, totals R$ 14,760,026.67 (about US$ 3 million)
It is with great pleasure that we announce the approval of our proposal in the PUBLIC SELECTION MCTI/FINEP/FNDCT Economic Subsidy for Innovation in Continuous Flow – MORE INNOVATION BRAZIL – HEALTH/COMPANIES – RESEARCH, DEVELOPMENT AND INNOVATION TO REDUCE THE VULNERABILITIES OF SUS (BRAZIL’S PUBLIC HEALTH SYSTEM) AND EXPAND ACCESS TO HEALTHCARE. This relevant grant from FINEP, in the amount of R$ 13,693,706.67, with a contribution from Nintx in the amount of R$ 1,066,320.00, totaling R$ 14,760,026.67 (about US$ 3 million), will allow the company to complete the preclinical development of a multi-target therapy, with global reach, indicated for the treatment of inflammatory bowel disease, based on a medicinal plant with very promising results obtained in the proof of concept studies performed so far. This project already has a partnership with the Center for Innovation and Preclinical Studies (CIEnP), with the support of Embrapii (Brazilian Company of Industrial Research and Innovation), and with the expertise of Centroflora, a world leader in the manufacturing of plant-based active pharmaceutical ingredients. In this way, Nintx articulates the Brazilian innovation ecosystem, promoting the generation of radical pharmaceutical innovations from Brazil to the world!
To have access to the full content, check us out on LinkedIn.
Commenti